Suppr超能文献

用D型氨基酸合成的抗菌肽的抗菌和抗炎活性

Antibacterial and Anti-Inflammatory Activity of an Antimicrobial Peptide Synthesized with D Amino Acids.

作者信息

Brunetti Jlenia, Carnicelli Veronica, Ponzi Alessia, Di Giulio Antonio, Lizzi Anna Rita, Cristiano Loredana, Cresti Laura, Cappello Giovanni, Pollini Simona, Mosconi Lara, Rossolini Gian Maria, Bracci Luisa, Falciani Chiara, Pini Alessandro

机构信息

Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy.

Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, 67100 L'Aquila, Italy.

出版信息

Antibiotics (Basel). 2020 Nov 24;9(12):840. doi: 10.3390/antibiotics9120840.

Abstract

The peptide SET-M33 is a molecule synthesized in tetra-branched form which is being developed as a new antibiotic against Gram-negative bacteria. Its isomeric form with D amino acids instead of the L version (SET-M33D) is also able to kill Gram-positive bacteria because of its higher resistance to bacterial proteases (Falciani et al., , 2012, 7, e46259). Here we report the strong in vitro activity of SET-M33D (MIC range 0.7-6.0 µM) against multiresistant pathogens of clinical interest, including Gram-positives , , and , and various Gram-negative enterobacteriaceae. SET-M33D antibacterial activity is also confirmed in vivo against a MRSA strain of with doses perfectly compatible with clinical use (5 and 2.5 mg/Kg). Moreover, SET-M33D strongly neutralized lipopolysaccharide (LPS) and lipoteichoic acid (LTA), thus exerting a strong anti-inflammatory effect, reducing expression of cytokines, enzymes, and transcription factors (TNF-α, IL6, COX-2, KC, MIP-1, IP10, iNOS, NF-κB) involved in the onset and evolution of the inflammatory process. These results, along with in vitro and in vivo toxicity data and the low frequency of resistance selection reported here, make SET-M33D a strong candidate for the development of a new broad spectrum antibiotic.

摘要

肽SET-M33是一种以四分支形式合成的分子,正被开发为一种新型抗革兰氏阴性菌抗生素。其具有D型氨基酸而非L型氨基酸的异构体形式(SET-M33D),由于对细菌蛋白酶具有更高的抗性,也能够杀死革兰氏阳性菌(Falciani等人,2012年,7卷,e46259)。在此,我们报告了SET-M33D在体外对临床相关的多重耐药病原体具有强大活性(MIC范围为0.7 - 6.0 μM),包括革兰氏阳性菌、、和,以及各种革兰氏阴性肠杆菌科细菌。SET-M33D的抗菌活性在体内针对的耐甲氧西林金黄色葡萄球菌菌株也得到证实,所用剂量与临床使用完全兼容(5和2.5 mg/Kg)。此外,SET-M33D能强烈中和脂多糖(LPS)和脂磷壁酸(LTA),从而发挥强大的抗炎作用,降低参与炎症过程发生和发展的细胞因子、酶和转录因子(TNF-α、IL6、COX-2、KC、MIP-1、IP10、iNOS、NF-κB)的表达。这些结果,连同此处报告的体外和体内毒性数据以及低频率的耐药性选择,使SET-M33D成为开发新型广谱抗生素的有力候选物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db32/7760307/15862ef8c713/antibiotics-09-00840-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验